Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6132415

Nc1nnc(-c2ccc(C3CCN(C4CCCCC4)CC3)cc2)s1.O=C(O)C(F)(F)F

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 2/20 0.44
CSNK2A2 P19784 1/20 0.43
CSNK2B P67870 1/20 0.43
CSNK2A1 P68400 1/20 0.43
HRH3 Q9Y5N1 9/20 0.41
GPR119 Q8TDV5 1/20 0.38
MGAM O43451 1/20 0.38
GAA P10253 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
C1S P09871 1/20 0.38
HRH2 P25021 1/20 0.36
HRH1 P35367 1/20 0.36
HRH4 Q9H3N8 1/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
EGFR P00533 1/20 0.36
LCK P06239 1/20 0.36
JAK3 P52333 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6134894 0.82 CSNK2A2 (0.41) SLC18A3CSNK2A2CSNK2BCSNK2A1HRH3
Trifluoroacetic Acid SCHEMBL6133865 0.76 MAOB (0.40) SLC18A3CSNK2A2CSNK2BCSNK2A1HRH3
Trifluoroacetic Acid SCHEMBL6937886 0.74 TP53 (0.42) SLC18A3HRH3
SCHEMBL6134375 0.73 HRH3 (0.52) HRH3KDM4E
Trifluoroacetic Acid SCHEMBL22608185 0.69 HAO1 (0.52)
SCHEMBL7334743 0.68 CSNK2A2 (0.56) CSNK2A2CSNK2BCSNK2A1KDM4E
SCHEMBL16764376 0.68 SLC18A3 (0.69) SLC18A3HRH3
Hydrochloric Acid SCHEMBL6132468 0.67 MKNK1 (0.48) SLC18A3HRH3
SCHEMBL27484843 0.67 SLC18A3 (0.63) SLC18A3KDM4E
Trifluoroacetic Acid SCHEMBL7317798 0.66 CSNK2A2 (0.59) CSNK2A2CSNK2BCSNK2A1GPR119MGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884774-B2 Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-26 US disclosed
EP-1259535-B1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-04-13 EP disclosed
CN-1425026-A Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO (JP) 2003-06-18 CN disclosed
US-20030083238-A1 Cyclic hexapeptide derivatives ASTELLAS PHARMA INC. (JP) 2003-05-01 US disclosed
EP-1259535-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2001060846-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083238-A1 Cyclic hexapeptide derivatives NGLY1, ALG1, CHIT1 SLC18A3 4707/4885CSNK2A2 1792/4885CSNK2B 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.